TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05123300

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: 18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
Study: NCT05511012

Intervention type: OTHER
Group type: OTHER
Intervention: motion control fault tests
Description: Patients make 6 motion control fault tests, in the same order. Each test is performed three times
Study: NCT04935255

Intervention type: OTHER
Intervention: Blood sampling - Pharmacokinetic assessment
Description: Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
Study: NCT04658927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.4mg
Description: iLUX + dextenza

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone acetate
Description: Prednisolone acetate 1% and iLux

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: iLUX alone.
Study: NCT05894408

Intervention type: OTHER
Intervention: this is no intervention
Description: this is no intervention

Intervention type: OTHER
Intervention: this is no intervention
Description: this is no intervention
Study: NCT05379738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 sessions of adapted physical activity after stem cell transplant
Description: physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary
Study: NCT06087081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Treatment along with Mill's manipulation
Description: Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena
Description: In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks
Study: NCT05229406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMP app
Description: The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMP app
Description: The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
Study: NCT05668676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone arm
Description: 2 tabs of 20 mg prednisone per day during 7 days added to usual care medications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
Study: NCT04671342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamKit
Description: The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
Study: NCT05321966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual video education
Description: The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
Study: NCT06260904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg twice daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15 mg weekly orally
Study: NCT04429152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir
Description: DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
Study: NCT06022939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study: NCT05657509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
Study: NCT06069609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifilcon a Contact Lens for Astigmatism
Description: Kalifilcon A Daily Disposable Toric Contact Lens for Astigmatism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys 1-Day for Astigmatism
Description: Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism
Study: NCT04488133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm.
Study: NCT05224934

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultra-hypofractionated radiotherapy
Description: stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
Study: NCT06255301

Intervention type: DIAGNOSTIC_TEST
Intervention: EYEPRIM
Description: Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.

Intervention type: DIAGNOSTIC_TEST
Intervention: EYEPRIM
Description: Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.

Intervention type: DIAGNOSTIC_TEST
Intervention: EYEPRIM
Description: Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
Study: NCT06024083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy skills video intervention
Description: A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
Study: NCT06139107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150mg twice a day for 3 cycles prior to radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg daily
Study: NCT04795011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and manual lymphatic drainage
Description: MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: range of motion and walking exercise
Study: NCT06131905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
Study: NCT04923243

Intervention type: PROCEDURE
Intervention: hip/knee replacement
Description: hip/knee replacement

Intervention type: PROCEDURE
Intervention: hip/knee replacement
Description: hip/knee replacement
Study: NCT06286449

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal tap
Description: A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
Study: NCT05808842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeraVe
Description: * CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CeraVe and Calecim
Description: * CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside
Study: NCT05459233

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doppler-echocardiography
Description: The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
Study: NCT05381558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: local injection in sinus tarsi
Study: NCT05648981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block administration with laser irradiation
Description: Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Alveolar Nerve Block administration
Description: Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
Study: NCT06014749

Intervention type: PROCEDURE
Intervention: undergo
Description: regional anesthesia

Intervention type: PROCEDURE
Intervention: undergo
Description: regional anesthesia

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound guided

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound guided

Intervention type: DRUG
Intervention: Local anesthetic
Description: local anesthetic
Study: NCT06110559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation.
Study: NCT05632237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family strengthening program
Description: Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting.
Study: NCT05370274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training intervention
Description: The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial nerve non-invasive neuromodulation (CN-NINM)
Description: During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
Study: NCT04951765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
Study: NCT06014749

Intervention type: DRUG
Intervention: Local anesthetic
Description: local anesthetic
Study: NCT04951765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
Study: NCT06284239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tell me about the game.
Description: It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
Study: NCT05008458

Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand factor and copeptin
Description: biomarkers increase in children with febrile seizures

Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand factor and copeptin
Description: biomarkers increase in children with febrile seizures

Intervention type: DIAGNOSTIC_TEST
Intervention: von willebrand factor and copeptin
Description: biomarkers increase in children with febrile seizures
Study: NCT05418569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention arm - A new smartphone application for pediatric type 1 DM
Description: An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard diabetic eduction
Description: Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
Study: NCT04273542

Intervention type: OTHER
Group type: OTHER
Intervention: liquid biopsy
Description: Blood sample collection during follow-up of the three cohorts of patients

Intervention type: OTHER
Group type: OTHER
Intervention: liquid biopsy
Description: Blood sample collection during follow-up of the three cohorts of patients

Intervention type: OTHER
Group type: OTHER
Intervention: liquid biopsy
Description: Blood sample collection during follow-up of the three cohorts of patients
Study: NCT05459233

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive hemodynamic measurements
Description: The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
Study: NCT06081075

Intervention type: OTHER
Intervention: Genetic testing
Description: Rapid whole genome sequencing
Study: NCT05705856

Intervention type: DRUG
Intervention: Ustekinumab
Description: Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.

Intervention type: DRUG
Intervention: Ustekinumab
Description: Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.